Dr Reddy’s Laboratories, or any other Suboxone (buprenorphine/naloxone) sublingual film abbreviated new drug application (ANDA) filer, will face immediate competition from brand manufacturer Indivior’s authorized generic upon market entry of their ANDA product, the originator has confirmed as part of a trading update.
Indivior has also doubled down on plans to file by 20 December a petition for a rehearing by the original panel of US Court of Appeals judges of their 20 November decision vacating a preliminary injunction against Reddy’s
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?